Det er påvist, at behandling med pioglitazon reducerer leverens glukoseproduktion og forøger den perifere deponering af glukose i tilfælde af insulinresistens.
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.